Abstract 1461P
Background
The optimal duration of ICIs treatment in mNSCLC is debated, arbitrarily fixed to 2 years in the 1st line setting. Unfortunately, pts will mostly relapse months or years after the end of the treatment (EOT). Physicians tend to confirm the partial or complete obtained response before stopping it, by performing 18F-FDG -PET (PET). However, the interpretation of residual fixative areas remains unclear.
Methods
This is a bi-center retrospective study of mNCSLC pts who completed 2 years of ICI, or stopped it due to adverse event without progression and underwent a PET at the EOT. Collected data were: age, smoking status, PDL1 and KRAS status, type and line of treatment, ICI duration.
Results
We enrolled 80 pts who began ICIs between Sept. 2016 and Nov. 2021. Median follow up was 35.9 months. Median age was 61 years (range: 56-69), sex ratio was 1:1, 93.5% were current/former smokers, 87.5% had adenocarcinoma, 54% had PDL1>50%. ICI was given as monotherapy and as first line in 41% and 67.5% of pts respectively. Molecular analysis revealed KRAS G12C mutation in 29% pts. Median ICIs duration was 23.4 months (range: 3-48), 55 pts completed 2 years of ICI, 22 discontinued due to toxicity, 3 for others reasons. The 2-year progression-free survival (PFS) probability was 96% (range:92-100). Median SUVmax was 1.9 (range: 0-17). 55% pts had PET residual fixation (RF): 36% on initial lung tumor, 15% on mediastinal lymph nodes and 5% on extrathoracic sites. 6 pts underwent an excision surgery or a biopsy of a RF: 4 were immune-mediated inflammatory reactions, 2 found the initial histology. 6 pts were locally treated for RF by radiotherapy or surgery. Of the 17 pts who relapsed: 12 had a RF on the PET after ICIs. Conversely, 5/36 pts (14%) without RF relapsed. The presence of a RF was not associated with the PFS in univariable analysis (HR=2.4, 95%CI: 0.8-6.9, P=.121) and after adjusting for duration and type of ICI treatment (HR=1.4, 95%CI: 0.5-4.3, P=.539).
Conclusions
Positive 18F-FDG-PET/CT is not associated with relapse after completion of ICI treatment but has good negative predictive value. Treatment of oligopersistence after partial response to ICI based on PET-scan remains controversial.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sophie Cousin.
Funding
Has not received any funding.
Disclosure
C. Domblides: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD; Financial Interests, Personal, Other, travel expenses: AstraZeneca, BMS, MSD. All other authors have declared no conflicts of interest.
Resources from the same session
1422P - Comprehensive genomic profiling (CGP) changes management and improves survival in patients with advanced non-small cell lung cancer (aNSCLC)
Presenter: George Simon
Session: Poster session 20
1423P - Clinical impact of radiological diagnosis of lymphangitic carcinomatosis in patients with extensive non-small cell lung cancer treated with immunotherapy
Presenter: Anita Bolina
Session: Poster session 20
1424P - Outcome of thromboembolic events and its influence on survival time of advanced NSCLC patients receiving antiangiogenic therapy
Presenter: Wei-Fan Ou
Session: Poster session 20
1425P - Clinical utility of liquid biopsy for the early diagnosis of EGFR mutant advanced lung cancer in real-life setting (CLEAR)
Presenter: Rola El Sayed
Session: Poster session 20
1427P - Exploration of the value of leptomeningeal biopsy in diagnosing and treating non-small cell lung cancer with leptomeningeal metastasis
Presenter: Lin Cai
Session: Poster session 20
1428P - Clinical benefit of combination chemo-immunotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic NSCLC
Presenter: Thierry Landre
Session: Poster session 20
1429P - Homologous recombination repair (HRR) gene mutation: A novel biomarker for precision genomics testing in advanced lung cancer
Presenter: Madhu Nagaraj
Session: Poster session 20
1430P - Excellent performance of a fast and fully-automated RNA based genefusion assay conducted on a large fusion positive non-small cell lung cancer cohort within a multicenter study
Presenter: Arndt Hartmann
Session: Poster session 20
1431P - The nNGM Preclinical Platform: Preclinical research to generate evidence for patients with non-small cell lung cancer harboring variants of unknown significance
Presenter: Martin Ziegler
Session: Poster session 20